<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0002959'>Microalbuminuria</z:mp>, an early feature of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, indicates intrarenal endothelial damage </plain></SENT>
<SENT sid="1" pm="."><plain>In type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:mp ids='MP_0002959'>microalbuminuria</z:mp> is strongly related to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore investigated whether <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, an <z:chebi fb="0" ids="50864">insulin-sensitizing drug</z:chebi> that is known to improve <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e>, was able to improve intrarenal <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and <z:mp ids='MP_0002959'>microalbuminuria</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Nineteen type 2 diabetic patients participated in this double-blind cross-over trial </plain></SENT>
<SENT sid="4" pm="."><plain>Nine patients with newly diagnosed disease without <z:mp ids='MP_0002959'>microalbuminuria</z:mp> were randomized to a treatment with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> or nateglinide, each for 12 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>Ten patients with <z:mp ids='MP_0002959'>microalbuminuria</z:mp> were randomized to <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> or placebo, each for 12 weeks in addition to their previous <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> medication </plain></SENT>
<SENT sid="6" pm="."><plain>After each treatment, glomerular filtration rate (GFR), renal plasma flow, and filtration fraction were measured before and after blockade of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) by intravenous administration of <z:chebi fb="0" ids="28229">N-monomethyl-L-arginine</z:chebi>-<z:chebi fb="49" ids="30089,47622">acetate</z:chebi> (<z:chebi fb="0" ids="28229">L-NMMA</z:chebi>) </plain></SENT>
<SENT sid="7" pm="."><plain>Ten healthy subjects served as control subjects </plain></SENT>
<SENT sid="8" pm="."><plain>Type 2 diabetic patients at baseline showed glomerular hyperfiltration compared with healthy control subjects </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> reduced elevated GFR and filtration fraction toward control primarily in patients with <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (GFR: 133.4 +/- 9.8 vs. 119.6 +/- 8.7 ml/min; filtration fraction: 23.2 +/- 1.7 vs. 20.5 +/- 1.6% before and after <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, respectively; control subjects: GFR 111.7 +/- 8.6 ml/min, filtration fraction 20.4 +/- 1.5%) </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> improved intrarenal NO bioavailability in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> toward control as shown by infusion of <z:chebi fb="0" ids="28229">L-NMMA</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> <z:mp ids='MP_0005540'>reduced albumin excretion</z:mp> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with <z:mp ids='MP_0002959'>microalbuminuria</z:mp> from 116.5 +/- 31 to 40.4 +/- 12 mg/day </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> ameliorated glomerular hyperfiltration in early type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, improved NO bioavailability, and lessened renal end-organ damage in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with <z:mp ids='MP_0002959'>microalbuminuria</z:mp> </plain></SENT>
</text></document>